ArticleFrontiers in neuroscience2025
Efficacy of cardioneuroablation for vasodepressor vasovagal syncope.
Article in Frontiers in neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Syncope in AQP4-IgG-positive neuromyelitis optica spectrum disorder: a case series and literature review.Frontiers in neuroscience · 2026Article
- Cardioneuroablation for Vasovagal Syncope: An Updated Systematic Review and Single-Arm Meta-Analysis.Biomedicines · 2025Review
- Cardioneuroablation for Asystolic Reflex Syncope: How to Identify the Best Candidate and How to Predict Success.Arrhythmia & electrophysiology review · 2025Review
- Evaluation of the clinical value of heart rate variability in predicting vasovagal syncope.Frontiers in cardiovascular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Cardioneuroablation (CNA) is effective for cardiac inhibitory and mixed vasovagal syncope (VVS) but not for vasodepressor VVS. This study aimed to assess the therapeutic benefits of CNA in vasodepressor VVS. Methods: VVS patients hospitalized in the Department of Cardiology of Jiangxi Provincial People's Hospital were retrospectively reviewed. Holter monitoring was performed before, during, and 3 months after CNA. Changes in heart rate and atrioventricular conduction before and after ablation were compared. Results: Thirty-five patients (18 M/17F, 47.48 ± 16.49 years) were included. Median duration of syncope was 24.0 months (range, 2.5-66.0). Median number of syncope episodes before treatment was two (range, 2-4). The time domain indexes of heart rate variability, mean heart rate, maximum heart rate, and minimum heart rate were significantly higher 3 months after CNA. Mean follow-up was 11 ± 4.67 months. Recurrent syncope occurred in two patients with vasodepressor VVS, one of them with presyncope symptoms in vasodepressor type; and one patient occurred with mixed VVS, without presyncope symptoms. The syncope free survival is 76.92%. No serious complications occurred. CNA is safe and effective in the treatment of vasodepressor VVS. Conclusion: CNA is effective for treating vasodepressor VVS. Our study provides a theoretical basis for individualization of treatment in patients with vasodepressor VVS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.